GeoVax Labs (GOVX)

GeoVax Labs (GOVX) Stock Price & Analysis


GOVX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.53 - $4.30
Previous Close$0.62
Average Volume (3M)306.68K
Market Cap
Enterprise Value-$7.69M
Total Cash (Recent Filing)$23.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.9
Aug 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding26,443,649
10 Day Avg. Volume498,270
30 Day Avg. Volume306,684
Standard Deviation0.53
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.05
Price Target Upside746.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was GeoVax Labs’s price range in the past 12 months?
GeoVax Labs lowest stock price was $0.53 and its highest was $4.30 in the past 12 months.
    What is GeoVax Labs’s market cap?
    Currently, no data Available
    When is GeoVax Labs’s upcoming earnings report date?
    GeoVax Labs’s upcoming earnings report date is Aug 09, 2023 which is in 69 days.
      How were GeoVax Labs’s earnings last quarter?
      GeoVax Labs released its earnings results on May 04, 2023. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.203 by $0.053.
        Is GeoVax Labs overvalued?
        According to Wall Street analysts GeoVax Labs’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does GeoVax Labs pay dividends?
          GeoVax Labs does not currently pay dividends.
          What is GeoVax Labs’s EPS estimate?
          GeoVax Labs’s EPS estimate is -$0.17.
            How many shares outstanding does GeoVax Labs have?
            GeoVax Labs has 26,443,650 shares outstanding.
              What happened to GeoVax Labs’s price movement after its last earnings report?
              GeoVax Labs reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.203. Following the earnings report the stock price went down -3.077%.
                Which hedge fund is a major shareholder of GeoVax Labs?
                Currently, no hedge funds are holding shares in GOVX


                GeoVax Labs Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                GeoVax Labs

                GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.


                Top 5 ETFs holding GOVX

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold GOVX. The ETFs are listed according to market value of GOVX within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                bioAffinity Technologies, Inc.
                Neoleukin Therapeutics
                AgeX Therapeutics
                Forte Biosciences

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis